[A23-52] Trastuzumab deruxtecan (breast cancer) – Addendum to Commission A23-07
Last updated 20.07.2023
Project no.:
A23-52
Commission:
Commission awarded on 06.06.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy
- Patients with visceral disease: indication of minor added benefit
- Patients without visceral disease: indication of major added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A23-07 | Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2023-07-20 A G-BA decision was published.